Bristol Myers said its next-gen multiple myeloma drug cut rates of detectable cancer. Will it get FDA approval?

Bristol Myers Squibb said a regimen that includes its experimental drug iberdomide led to no detectable cancer cells in a greater proportion of multiple myeloma patients than those who received standard treatments in a pivotal ...